Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21557884 | 0.78 | ALDH1A1 (0.38) | LMNAUSP2ALDH1A1CYP1A2TSHR | |
| SCHEMBL1820480 | 0.77 | NR1H2 (0.43) | USP2SMN1; SMN2 | |
| SCHEMBL29281603 | 0.74 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL28765338 | 0.72 | HSD11B1 (0.32) | — | |
| SCHEMBL23070877 | 0.71 | EPHX1 (0.47) | USP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3379442 | 0.71 | SLC6A9 (0.46) | LMNAALDH1A1TSHR | |
| SCHEMBL1818822 | 0.71 | HSD11B1 (0.39) | NAMPTALDH1A1 | |
| SCHEMBL27869525 | 0.70 | USP2 (0.32) | LMNAUSP2ALDH1A1CYP1A2TSHR | |
| SCHEMBL1972942 | 0.70 | SLC6A2 (0.33) | LMNAUSP2ALDH1A1CYP1A2TSHR | |
| SCHEMBL4132172 | 0.69 | POLB (0.44) | NAMPTLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947714-B2 | Piperidine glycine transporter inhibitors | Merck, Sharp & Dohme Corp. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC1A3 | NAMPT 792/4885LMNA 4136/4885USP2 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.